DiaMedica Therapeutics Inc (DMAC) Wheel Strategy

Running a DMAC wheel strategy lets you generate consistent premium income on DiaMedica Therapeutics Inc while setting your own entry and exit prices on the underlying. DiaMedica Therapeutics Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own DMAC, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best DMAC wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on DMAC, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable DMAC wheel from a losing one.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the DMAC wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your DMAC wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.